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Abstract
Small ubiquitin-like modifier (SUMO) proteins regulate many important eukaryotic cellular processes through reversible
covalent conjugation to target proteins. In addition to its many well-known biological consequences, like subcellular
translocation of protein, subnuclear structure formation, and modulation of transcriptional activity, we show here that
SUMO-2 also plays a role in mRNA translation. SUMO-2 promoted formation of the active eukaryotic initiation factor 4F
(eIF4F) complex by enhancing interaction between Eukaryotic Initiation Factor 4E (eIF4E) and Eukaryotic Initiation Factor 4G
(eIF4G), and induced translation of a subset of proteins, such as cyclinD1 and c-myc, which essential for cell proliferation and
apoptosis. As expected, overexpression of SUMO-2 can partially cancel out the disrupting effect of 4EGI-1, a small molecule
inhibitor of eIF4E/eIF4G interaction, on formation of the eIF4F complex, translation of the cap-dependent protein, cell
proliferation and apoptosis. On the other hand, SUMO-2 knockdown via shRNA partially impaired cap-dependent translation
and cell proliferation and promoted apoptosis. These results collectively suggest that SUMO-2 conjugation plays a crucial
regulatory role in protein synthesis. Thus, this report might contribute to the basic understanding of mammalian protein
translation and sheds some new light on the role of SUMO in this process.
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Introduction
Small ubiquitin-like modifiers (SUMO) are ubiquitin-related
proteins that can be covalently conjugated to target proteins in
cells to modify their function. To date, four SUMO isoforms
encoded by separate genes, designated SUMO-1 to SUMO-4,
have been identified in humans [1,2]. The sequence identity and
expression of these four SUMO molecules is highly variable.
SUMO-2 and SUMO-3 are nearly identical, but share only 50%
identity with SUMO-1 [3–5]. While SUMO-1, -2 and -3 are
expressed ubiquitously, SUMO-4 seems to be expressed mainly in
the kidney, lymph nodes and spleen.
Protein sumoylation is mediated by activating (E1), conjugating
(E2) and ligating (E3) enzymes [6]. Ubc9 is the only identified
SUMO E2 conjugating enzyme, which is sufficient for sumoyla-
tion. The E3 ligase promotes the efficiency of sumoylation and in
some cases has been shown to direct SUMO conjugation onto
non-consensus motifs [7]. Furthermore, sumoylation is reversible
and is removed from targets by several specific SUMO proteases
in an ATP-dependent manner [8].
SUMO modification has emerged as an important regulatory
mechanism for protein activity, stability and localization. Most of
the SUMO targets identified thus far are involved in various
cellular processes, such as nucleocytoplasmic transport, transcrip-
tional regulation, apoptosis, response to stress, and cell cycle
progression [9]. Sumoylation regulates several aspects of gene
expression, including DNA transcription, mRNA splicing and
mRNA polyadenylation [7,9,10]. Furthermore, our recent study
demonstrated that SUMO modification also regulates protein
translation [11].
In eukaryotes, most proteins are synthesized through cap-
dependent mRNA translation. A rate-limiting stepof this process is
formation of the eIF4F complex containing eIF4E (cap-binding
protein), eIF4A (ATP-dependent mRNA helicase) and eIF4G
(scaffold protein) [12]. Binding of eIF4G to the cap structure of
mRNA is competed by a small family of eIF4E-binding proteins
(4E-BPs). 4E-BP1 is the most abundant member of the 4E-BP
family. Its phosphorylation sites of Ser65 and Thr70 have been
shown to participate in formation of the eIF4F complex. In
particular, eIF4E phosphorylation at Ser209 and eIF4E SUMO
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conjugation by SUMO-1 seems to be important for initiation of
cap-dependent translation [11,13]. Furthermore, we found that
overexpression of UBC9, the only identified SUMO E2 conju-
gating enzyme, dramatically increased expression of a cap-
dependent luciferase reporter, but overexpression of SUMO-1
only slightly increased the expression of the luciferase reporter.
Thus, we speculated that SUMO-2/3 isoform conjugations are
involved in the regulation of cap-dependent mRNA translation.
However, whether SUMO-2/3 conjugation plays a role in the
regulation of cap-dependent mRNA translation and the innate
mechanisms are still unclear.
In this study, we characterized the role of SUMO-2 conjugation
in mRNA translation initiation through a SUMO-2 motif-negative
mutation, overexpression and shRNA interference experiments, a
translation reporter assay, and an inhibitor treatment. Further-
more, we studied the effect of regulation of mRNA translation by
SUMO-2 on cell proliferation and apoptosis.
Materials and Methods
Cell culture and drug treatments
Human colorectal cancer HCT 116 cells were purchased from
ATCC (ATCC, Manassas, VA, USA). Cells were grown in a
humidified incubator with 5% CO2 at 37uC in McCoy’s 5A
Medium (Invitrogen) supplemented with 10% fetal bovine serum
(FBS). For serum starvation and stimulation experiments, the cells
were seeded and maintained in McCoy’s 5A Medium plus 10%
FBS. The following day, the cells were washed twice in Dulbecco’s
phosphate buffered saline (D-PBS) and maintained in McCoy’s 5A
Medium with 0.2% FBS. Twelve hours later, the cells were
stimulated with or without 20% FBS for an additional 2 h. eIF4E/
eIF4G Interaction Inhibitor (4EGI-1) (50 mM, Santa Cruz, CA)
was added to the appropriate media at the indicated times for
24 h.
Plasmids, Mutagenesis and Transfection
The PCR-amplified cDNAs encoding the processed forms of
SUMO-1, SUMO-2, and SUMO-3 containing Gly-Gly at their
C-termini were inserted into the pcDNA3-HA3 vector, which was
described previously [11]. EcoR I (EcoR V for SUMO-1)/Apa I
fragments were used to generate pcDNA3-HA3-SUMO-1/2/3
plasmids. The pcDNA3-HA3-SUMO-D1/2/3 plasmids lacking
the C-terminal Gly-Gly were constructed using 39-primers
specifically designed with the corresponding mutation. The
shRNA oligos were designed and subcloned into pLKO.1 (Puro)
according to the Addgene Plasmid 10878 protocol. A negative
control vector containing scrambled shRNA was constructed using
the same method. Transient transfections were performed using
PolyJet (SignaGen Laboratories, Ijamsville, MD) according to
attached protocol. The cells were harvested 48 h after transfection.
For the shRNA knockdown of SUMO-2, the cells were selected by
puromycin for approximately 7 d. The gene-silencing effect was
evaluated by Western blot analysis.
Extract preparation, immunoprecipitation and Western
blotting
The cells were washed twice with cold PBS and harvested in
RIPA lysis buffer containing 1% NP-40, 50 mM Tris-base
(pH 7.4), 2.5% sodium deoxycholate, 1 mM EDTA, 150 mM
NaCl, and a protease inhibitor cocktail (Sigma) (1 pill/10 ml of
lysis buffer). The cell debris were pelleted by centrifugation, and
the protein concentration in the supernatant was measured using
the Coomassie brilliant blue G-250 assay. For immunoprecipita-
tion to detect the interactions between eIF4E, eIF4G and eIF4A, a
total of 300 mg of protein was then mixed with the corresponding
antibody and rotated overnight at 4uC. The immunocomplexes
were recovered by incubating with Protein G-Sepharose for 4 h,
and the resin was washed five times with RIPA lysis buffer. The
samples were separated using sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) and transferred to
polyvinylidene difluoride membranes. Immunoblotting was per-
formed with antibodies against Mammalian Target of Rapamycin
(mTOR), phospho-Ser2448 mTOR, p70 S6 kinase, phospho-
Thr421/Ser424 p70 S6 kinase, 4E-BP1, phospho-Thr37/46 4E-
BP1, phospho-Thr70 4E-BP1, S6, phospho-Ser235/236 S6,
eIF4E, and phospho-Ser209 eIF4E (Cell Signaling, Beverley,
MA); eIF4AI/II, HA, c-myc (Santa Cruz, Inc., CA); eIF4G1/
eIF4GI (Bethyl Laboratories, Inc.); and beta-actin (Abcam, Inc.,
Cambridge, MA).
Cap-dependent reporter gene assay
As previously described [14], transcription from reporter gene
pYIC DNA produces a bicistronic mRNA encoding epitope-
tagged yellow fluorescent protein (EYFP) and cyan fluorescent
protein. EYFP translation depends on 59 cap sequence,so if a
protein interfere with the cap-dependent pathway, EYFP transla-
tion is reduced. As EYFP were tagged with three c-myc epitope
tags, we can use the corresponding antibody against c-myc or
fluorescence intensity to indicate the expression of EYFP, and the
results will help us to decide whether the stimulus interferes with
protein translation through cap -dependent pathway.
m7GTP Pull-down Assay
The method has been described previously [15]. Briefly, 10 ml
of m7GTP Sepharose beads (Amersham) was washed with 500 ml
of PBS three times, added to 300 mg of total protein from the cell
lysates pre-cleared with Sepharose resin without m7GTP for
1 hour, and rotated overnight at 4uC. The beads were washed four
to five times with PBS. The samples were then denatured, and the
supernatants were loaded into SDS-PAGE for Western blot
analysis.
Reverse Transcription and PCR (RT-PCR)
Total RNA was isolated using the TRIzol reagent (Invitrogen,
Cincinnati, OH, USA) according to the manufacturer’s protocol.
RNA (1 mg) was reverse transcribed using Superscript II reverse
transcriptase with an oligo (dT) primer (Invitrogen, Carlsbad, CA).
The primers used to amplify the 281 bases of the human LUC
gene were 59-CCGGGAAAACGCTGGGCGTTA-39 and 59-
ACCTGCGACACCTGCGTCGA-39. The 202 bases of the
housekeeping gene b-actin were amplified using the following
primers: 59-CACCCGCCGCCAGCTCAC-39 and 59-CTTGCT-
CTGGGCCTCGTCGC-39.
Luciferase Activity Assay
The cells were seeded in 24-well plates and co-transfected with
the pcDNA3-HA3 reporter plasmid and the target plasmid using
the transfection reagent (5:1 ratio; Roche Applied Science)
following the manufacturer’s protocol. Twenty-four hours later,
the cells were lysed and subjected to a luciferase activity assay
using a luciferase assay system (Promega) in a luminometer. The
relative luciferase activity was normalized to b-galactosidase
activity, which was measured as described previously [16].
Cell growth rate analysis
In these experiments, 26104 cells were plated in each well of 48-
well plates and cultured for a 48 h period. Cell viability was
SUMO-2 Promotes Translation
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determined using the MTT assay [17]. Breifly, 50 ml of 5 mg/ml
MTT in PBS was added to each well and the plates incubated at
37uC for a further 4 h. The media as then removed and the purple
formazan crystals were dissolved in 150 ml dimethyl sulfoxide.
After the plate was agitated on a plate mixer, the optical densities
were read at 490 nm with a Bio-RAD microplate reader.
Apoptosis Assay
Serum starvation or 4EGI-1 induced apoptosis was assessed by
flow cytometric analysis of quantitate Annexin V-positive and
propidium iodide-positive cells. The HCT116 cells were trans-
fected with the scrambled shRNA or SUMO-2 shRNA. The stable
cell lines were established by puromycin (1 ng/ml) selection. The
stable cell lines were incubated in McCoy’s 5A Medium
containing 0.1% FBS for 72 h. After serum starvation, the
attached and floating cells were harvested. The cells were first
stained with propidium iodide and then with Annexin V-Alexa
Fluor 488 conjugate (Invitrogen) according to the manufacturer’s
instructions. Flow cytometry was used to quantify the Annexin V-
positive and propidium iodide-positive cells. A minimum of 30,000
cells per measurement from triplicate samples were analyzed for
each experiment.
Statistical Analysis
The band intensity for RT-PCR assay and western-blot assay
was analyzed by using the UN-SCAN-IT gel-graph digitizing
Figure 1. SUMO-2 Promotes cap-dependent mRNA translation. (A) The effects of the overexpressed SUMO isoforms on cap-dependent LUC
activities. HCT116 cells were co-transfected with individual SUMO isoforms along with a luciferase reporter gene. Twenty-four hours later, the cells
were lysed, and the luciferase activity was measured using a luciferase assay kit (Promega). The absolute relative light units values were in the 107–108
range. The expression levels of SUMO proteins in the cell lysates are also shown. (B) SUMO-2 activates cap-dependent EYFP expression. HCT116 cells
were co-transfected with pYIC and SUMO-2 or SUMO-3. EYFP and ECFP were detected using c-myc and HA-tag antibodies, respectively. (C) The effect
of the overexpression of the SUMO isoforms on LUC mRNA transcription in HCT116 cells. Human HCT116 cells were transfected with each of the
SUMO isoforms. Twenty four hours after transfection, the cells were harvested, and the whole cell lysates were used for the RT-PCR assays. The
reporter gene LUC was detected. b-actin protein was used as the loading control. (D) The shRNA knockdown of SUMO-2 reduces LUC expression.
HCT116 stable cells lines with an empty vector or SUMO2 shRNA were selected on the basis of puromycin resistance, then transiently transfected with
the luciferase reporter gene. Twenty-four hours after transfection, the cells were harvested for the luciferase assay. The data is an average of 5
measurements of a single clone. The knockdown effects are also shown. The error bars represent the S.E. LUC, luciferase; shRNA, short hairpin RNA;
SUMO, small ubiquitin-related modifier; RT-PCR, reverse transcription and polymerase chain reaction; Vc, vector control.
doi:10.1371/journal.pone.0100457.g001
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software. Results are expressed as means 6 SE. Statistical analyses
were performed by one-way analysis of variance followed by
Dunnett’s post hoc or Tukey’s multiple comparison test using the
data obtained from three or five independent experiments.
Results
SUMO-2 promotes cap-dependent protein translation
To date, little attention has been given to the impact of the
individual SUMO paralogues, SUMO-1, SUMO-2 and SUMO-
3, on protein translation. To examine whether SUMOs affects
protein translation, we surveyed cap-dependent luciferase activity,
cap-dependent EYFP expression and IRES-dependent ECFP
expression under normal and SUMO over-expression conditions.
As shown in Fig. 1A, overexpression of SUMO-2 and SUMO-3 by
transient transfection induced a striking increase in cap-dependent
luciferase activity (almost 5-fold for SUMO-2 and 2.5-fold for
SUMO-3), while SUMO-1 had little effect on cap-dependent
translation (Fig. 1A). Furthermore, overexpression of SUMO-2
also significantly promoted expression of cap-dependent EYFP,
but not affected the expression of IRES-dependent ECFP. On the
other hand, the overexpression of SUMO-3 markedly increased
expression of IRES-dependent ECFP, but did not affect cap-
dependent EYFP (Fig. 1B).
To evaluate whether SUMO-2 promotes protein translation by
increasing total mRNA level, we ran RT-PCR for LUC genes.
However, there was no significant change between the control and
experimental groups (Fig. 1C). SUMO-2 also didn’t change
mRNA level of ECFP and EYFP (data no shown). In contrast with
the effect of overexpression, SUMO-2 knockdown via SUMO-2
Figure 2. The effects of SUMO-2 on cap-dependent protein translation are dependent on SUMO-2 conjugation. (A) The SUMO mutants
are unable to be covalently conjugated. HCT116 cells were transfected with the SUMO-2 isoforms and SUMO-2DGGmutant, respectively. The
expression levels of conjugated SUMO-2 proteins in the cell lysates are detected byanti-SUMO-2/3 antibody (the 97% high identity between SUMO-2
and SUMO-3). Positive control lower panels, SUMO-1 conjugating RanGAP1 are detected by anti-SUMO-1 antibody. (B) The non-conjugatable form of
SUMO-2 had no effect on cap-dependent LUC translation. HCT116 cells were co-transfected with a luciferase reporter gene and each of the SUMO
isoforms or the corresponding mutant. Twenty-four hours later, the cells were harvested for a luciferase assay. The absolute luciferase relative light
values were in the 107–108 range. Statistics were performed using a one-way analysis of variance followed by Tukey’s multiple comparison test using
the data obtained from five independent experiments. (C) The effects of the non-conjugatable SUMO-2 mutant on cap-dependent EYFP protein
expression. The empty vector, SUMO-2, and SUMO-2DGG were co-transfected with pYIC in HCT116 cells. EYFP was detected using anti-c-myc
antibody. The expression level of SUMO-2 and its mutant protein are also shown. SUMO-2DGG, the non-conjugatable form of SUMO-2that lacks di-
glycine.
doi:10.1371/journal.pone.0100457.g002
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shRNA reduced cap-dependent luciferase activity (Fig. 1D).
Collectively, these data indicate that sumoylation by SUMO-2
plays a positive role in cap-dependent protein translation.
SUMO-2 conjugation is a prerequisite for activating cap-
dependent protein translation
To exclude the possibility that SUMO-2 exerts its effect through
non-covalent modifications, we made SUMO non-conjugatable
mutants (mutants lacking the C-terminal Gly-Gly through which
SUMOs congjugate with the target protein) and used these
mutants to differentiate whether it was through covalent or non-
covalent conjugation that SUMO promoted mRNA translation.
In HCT116 cells, RanGAP1 is a major substrate of SUMO-1 and
SUMO-1 antibody recognizes covalently conjugation RanGAP1-
SUMO-1. Since SUMO-2 or SUMO-3 themselves can be
sumoylated because they contain an internal SUMO consensus
modification site, poly-SUMO-2 or SUMO-3 chains on SUMO-
modified substrates can be generated. Fig. 2A confirmed that the
SUMO mutants are unable to be covalently conjugated.The cap-
dependent reporterassay using the luciferase reporter (Fig. 2B) and
the EYFP reporter (Fig. 2C) both showed that SUMO-2/3 non-
conjugatable mutants lost the ability to induce cap-dependent
mRNA translation. These results suggested that cap-dependent
mRNA translation was induced mainly by covalent SUMO
conjugation to certain target proteins.
Figure 3. The effect of SUMO-2 on protein translation is achieved through enhancing the interaction between eIF4E and eIF4G. (A)
The overexpression of SUMO-2 didn’t activate the mTORC1 pathway. The empty vector, HA-SUMO-2, or HA-SUMO-2DGG were transfected into
HCT116 cells. The cell lysates were used for immunoblot analysis of the total and phosphorylated level of key molecules in the mTOR pathway. (B)
SUMO-2 promotes the formation of the eIF4F complex. The HCT116 cells were transfected with the empty vector, wild-type SUMO-2 or SUMO-2DGG.
Twenty-four hours after transfection, the cells were harvested and lysed for the m7GTP pull-down assays. The cap-bound eIF4E, eIF4G, and 4EBP1
were eluted from the 7-methyl-GTP (m7GTP)-Sepharose resin using 7-methyl-GDP (m7GDP) and detected by immunoblotting with the corresponding
antibodies. (C) SUMO-2 promotes the interaction between eIF4E and eIF4G. The HCT116 cells were transfected with the empty vector, wild-type
SUMO-2 or SUMO-2DGG. Twenty-four hours after transfection, the cells were harvested and lysed for the co-immunoprecipitation assays. The
immunoprecipitated eIF4E or eIF4A1/2- was blotted with eIF4G, and the immunoprecipitated eIF4G was blotted with eIF4E. (D) SUMO-2 is directly
conjugated to the eIF4F complex. Processed the same way as (B), but immunoblotted with HA antibody. eIF, eukaryotic translation initiation factor.
*, p,0.05 vs control; **, p,0.01 vs control.
doi:10.1371/journal.pone.0100457.g003
SUMO-2 Promotes Translation
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SUMO-2 promotes formation of the eIF4F complex by
enhancing interaction between eIF4E and eIF4G
Next, we investigated the mechanisms underlying the SUMO-2
induced cap-dependent mRNA translation. Firstly, we analyzed
whether SUMO-2 promotes protein translation through
mTORC1 signaling by over-expressing HA-SUMO-2 and non-
conjugatable HA-SUMO-2DGG in HCT116 cells. And it was
found that the whole mTOR pathway, including the total
expression and phosphorylation of key molecules (such as m-
TOR, p70S6K, S6, 4EBP1 and eIF4E) in the mTORC1 pathway,
showed no obvious changes after overexpression of SUMO-2 or its
non-conjugatable form (Fig. 3A).
Then, we examined the effect of SUMO-2 on interaction
between eIF4E, eIF4A and eIF4G. As expected, the amount of
eIF4E and eIF4G in the eIF4F complex increased markedly
following SUMO-2 overexpression while 4EBP-1 significantly
decreased (Fig. 3B). Furthermore, interactions between eIF4E and
eIF4G were also enhanced, while the interaction between eIF4G
and eIF4A was not affected (Fig. 3C).
In order to further study whether SUMO-2 promotes formation
of eIF4F complex directly, we preformed m7GTP pull-down assay
and immunoblotted with HA antibody. Intriguingly, when we
overexpressed SUMO-2, bands from about 36 kDa to the top
were detected, while the other two groups didn’t show the same
phenomenon (Figure. 3D). We first considered if the three major
components of eIF4F complex can be sumoylated by SUMO-2.
We know that bands below 130 kDa were not eIF4G-SUMO-2
for the molecular weight of eIF4G is 220 kDa. However, we can’t
exclude eIF4G may be sumoylated. Then we demonstrated if
eIF4E and eIF4A can be modified by SUMO-2 by immunopre-
cipitation, but the results turned out to be negative (data not
shown). For eIF4F complex contains dozens of other components,
it is possible that the substrates of SUMO-2 existing in eIF4F that
were not examined through above experiments, so it suggested
that more experiment need to be done to find substrate protein of
SUMO-2 in eIF4F complex.
SUMO-2 rescues the inhibiting effects of 4EGI-1 on the
interaction between eIF4E and eIF4G
To further confirm the idea that SUMO-2 promotes mRNA
translation by enhancing the interaction between eIF4E and
eIF4G, we used 4EGI-1, an eIF4E/eIF4G interaction inhibitor, to
interfere with the interaction between eIF4G and eIF4E. Using
m7GTP pull-down and an immunoprecipitation assay, we found
that 4EGI-1 indeed disrupted the formation of the eIF4F complex
by inhibiting the interaction between eIF4G and eIF4E, as
previously reported [18] (Fig. 4A and B). Intriguingly, overex-
pression of SUMO-2 partially inhibited the effect of 4EGI-1 on
interaction between eIF4E and eIF4G and increased formation of
eIF4F complex, while SUMO-2DGG had no such effect (Fig. 4A
and B). Furthermore, 4EGI-1 also inhibited cap-dependent LUC
and EYFP expression, and SUMO-2 overexpression partially
Figure 4. SUMO-2 partially rescues the effect of 4EGI-1 on cap-dependent luciferase translation and the interaction between eIF4E
and eIF4G. HCT116 cells were co-transfected with LUC (A) or pYIC (B) with Vc, wild-type SUMO-2 or SUMO-2DGG. The cells were treated with 4EGI-1
(50 mM) for 24 h immediately after transient transfection. (A) The cells were harvested for the luciferase assay. (B) The cell lysates were detected for
EYFP expression. HCT116 cells were transfected with Vc, wild-type SUMO-2 or SUMO-2DGG. Twenty-four hours post-transfection, the cells were
treated with 4EGI-1 (50 mM) for another 24 h. (C) The pull-down assays were conducted. (D) The interaction between eIF4E and eIF4G was evaluated
using a co-immunoprecipitation method. *, p,0.05 vs 4EGI-1-untreated control; **, p,0.01 vs 4EGI-1-untreated control; #, p,0.05 vs 4EGI-1-
untreated control; ##, p,0.01 vs 4EGI-1-untreated control.
doi:10.1371/journal.pone.0100457.g004
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reduced the inhibitory effect of 4EGI-1 on LUC and EYFP
expression (Fig. 4C and D). Taken together, our data indicate that
overexpression of SUMO-2 partially induces cap-dependent
mRNA translation by promoting the interaction between eIF4E
and eIF4G and enhancing formation of active eIF4F complexes.
SUMO-2 upregulates expression of two cap-dependent
target proteins cyclin D1 and c-myc
Given that SUMO-2 substantially increases interaction between
eIF4E and eIF4G, we hypothesized that expression of cap-
dependent mRNA will also be promoted. To confirm this
hypothesis, we chose two typical cap-dependent proteins, cyclin
D1 and c-myc. We first determined the effect of 4EGI-1 on
expression of c-myc and cyclin D1. Consistent with our hypothesis,
4EGI-1 at a concentration of 50 mM inhibits the expression of cap-
dependent proteins, and overexpression of SUMO-2 can partially
reverse this inhibitory effect (Fig. 5A). Furthermore, neither
SUMO-2 nor 4EGI-1 affected the cytoplasmic mRNA levels of
the target genes (Fig. 5B), thus excluding the possibility that
SUMO-2 or 4EGI-1 alters gene transcription or mRNA transport
of the genes. On the contrary, expression of c-myc and cyclin D1
were significantly inhibited when SUMO-2 was reduced by
SUMO-2 shRNA (Fig. 5C), while their transcriptional levels were
also not affected (Fig. 5D). These observations suggest that
SUMO-2 upregulates two cap-dependent proteins c-myc and
cyclin D1 translation.
SUMO-2 promotes cell proliferation and inhibits
apoptosis
During culture of SUMO-2 silenced cells, we noticed that cells
in the silenced group have much lower rates of cell growth, which
was consistent witha previous study [19]. Thus, we assessed cell
proliferation and apoptosis. As expected, overexpression of
SUMO-2, but not SUMO-2DGG, significantly promotes cell
proliferation and partially cancels out the inhibitory effect of
4EGI-1 on HCT116 cell proliferation (Fig. 6A). On the other
hand, growth of SUMO-2-silenced HCT116 cells was markedly
inhibited (Fig. 6B). Furthermore, transient overexpression of
SUMO-2 markedly reduced HCT116 cell apoptosis induced by
4EGI-1 or starvation (Fig. 6, C and D). However, SUMO-2-
silencing HCT116 cells showed higher rates of apoptosis (Fig. 6E).
Taken together, these data indicate that SUMO-2 promotes cell
proliferation and inhibits apoptosis.
Discussion
Considering the remarkably extensive influence of sumoylation
in cells, it is important to identify whether the components in
sumoylation circulation impact protein translation. As previously
mentioned, both SUMO-1 and Ubc9 can promote protein
translation, and we suspected that SUMO-2 or SUMO-3 may
also play a part in mRNA translation. In this study, we provided
evidences to show that SUMO-2 can promote cap-dependent
protein translation, while SUMO-3 seems to be involved in IRES-
Figure 5. The effects of SUMO-2 on cap-dependent target proteins cyclin D1 and c-myc translation. HCT116 cells were transiently
transfected with empty vector, wild-type SUMO-2 or SUMO-2DGG and cultured for 24 h. Then, the cells were treated with 4EGI-1 (50 mM) for another
24 h and lysed for immunoblotting and RT-PCR. The control group was treated with DMSO. (A) The effect of the overexpression of SUMO-2 on the
expression of cyclin D1 and c-myc protein. **, p,0.01 vs 4EGI-1-untreated control; #, p,0.05 vs 4EGI-1-untreated control; ##, p,0.01 vs 4EGI-1-
untreated control. (B) The effect of the overexpression of SUMO-2 on cytosolic cyclin D1 and c-myc mRNAs levels. (C) The effect of SUMO-2
knockdown on the translation of the cap-dependent target proteins cyclin D1 and c-myc. *, p,0.05 vs control; **, p,0.01 vs control. (D) The effect of
SUMO-2 knockdown on cytosolic cyclin D1 and c-myc mRNAs levels. Stable SUMO-2 knockdown cell lines were established by puromycin (1 ng/ml)
selection. The cells were cultured in the puromycin free mediums for 24 h. The cells were then lysed and immunoblot and RT-PCR assays were
performed using the same methods as in A and B.
doi:10.1371/journal.pone.0100457.g005
SUMO-2 Promotes Translation
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dependent protein translation. Despite that the high homology of
the two isoforms brings great difficulty to characterization of the
functional specificity of the two proteins, our study showed that
SUMO-2 and SUMO-3 may play different roles in protein
translation. The underlying mechanisms need further investiga-
tion.
So what is the molecular basis of the SUMO-2 induced
activation of mRNA translation? We have four speculations.
Firstly, proteomic analyses have revealed that many of the SUMO
conjugation target proteins are transcription factors or other
nuclear proteins that modulate gene expression [20]. We also
know that mRNA levels of many known genes were significantly
up- or down-regulated in SUMO-2/-3 miRNA overexpressing
cells [19]. Thus, we examined whether SUMOs have effects on
total mRNA. However, total mRNA proved to be unchanged.
Secondly, the mTORC1 pathway is important for regulation of
mRNA translation and integrates various signals, such as
nutrients, growth factors, energy, and stress, to regulate cell
growth and proliferation. However, overexpression of SUMO-2
has little effect on the mTORC1 pathway. Thirdly, cap-dependent
translation is a fundamental operation in almost all aspects of cell
functions, and one of the rate-limiting step in cap-dependent
translation is the formation of the eIF4F complex containing
eIF4E (cap-binding protein), eIF4A (ATP-dependent mRNA
helicase) and eIF4G (scaffold protein). We found that the
underlying mechanism for this result is the significantly enhanced
interaction between eIF4E and eIF4G. The eIF4E/eIF4G
interaction inhibitor 4EGI-1 can effectively inhibit the formation
of active eIF4F complexes. After we treated HCT116 cells with
4EGI-1, the interaction between eIF4E and eIF4G was reduced
and this effect was partly impaired when SUMO-2 was
overexpressed. However, the effect was not reduced to the same
level as the control groups. This may be because 4EGI-1 [21] and
SUMO-2 [22] both have complicated networks within cells.
Fourthly, we found that SUMO-2 promotes mRNA translation
through covalent conjugation. Although the exact component of
eIF4F complex modified by SUMO-2 is yet to be identified despite
exclusion of three major components, our results did indicate that
SUMO-2 modification is involved in the formation of eIF4F
Figure 6. The effect of SUMO-2 on cell proliferation and apoptosis. (A) Overexpression of SUMO-2 promotes cell proliferation. The HCT-116
cells were infected with empty vector, wild-type SUMO-2, or SUMO-2DGG mutant. Twenty-four hours after transfection, the cells were treated with or
without 50 mM 4EGI-1 for another 24 h. Then, cell proliferation was evaluated using an MTT assay. (B) shRNA knockdown of SUMO-2 inhibits cell
proliferation. Stable SUMO-2 knockdown cell lines were established by puromycin (1 ng/ml) selection. The cells were cultured in the puromycin free
medium for 24 h, then evaluated with MTT assay. (C) Overexpression of SUMO-2 inhibits the apoptosis induced by starvation. Following the same
treatment described for A, the cells were then starved for 72 h, and apoptosis was measured using Annexin V staining. (D) Overexpression of SUMO-2
inhibits apoptosis induced by 4EGI-1. After the same treatment described for A, cell apoptosis as measured by using Annexin V staining. (E) The effect
of SUMO-2 knockdown on apoptosis. The percent in the upper left represents the dead cells, while the percent in the upper right represents the non-
viable apoptotic cells and dead cells. The percent in the lower right represents the viable apoptotic cells.
doi:10.1371/journal.pone.0100457.g006
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complex and promotes mRNA translation through the transla-
tional machinery.
shRNA was also used in this study to elucidate the effects of
silencing of SUMO expression on global protein expression. As
expected, after shRNA knockdown of SUMO-2, cap-dependent
LUC and EYFP protein translation decreased, which again
confirmed a role of SUMO-2 in protein translation. The shRNA
knockdown of SUMO-2 partially inhibited protein translation and
showed that SUMO-2 promotes mRNA translation. The observed
upregulation of mRNA translation appears to be a transient
process associated with formation of active eIF4F complexes
because the overall transcript levels for the relevant components
vary slightly between cells cultured normally versus cells cultured
under SUMO-2 overexpression conditions.
During mRNA translation, the rate-limiting step of translation
initiation is mediated by the cap-binding protein eIF4E [23]. Post-
translational modification and phosphorylation events are essential
for the translation promoting function of eIF4E. These include
phosphorylation of eIF4E [24–27] and its inhibitory binding
protein 4E-BP1 (PHAS-I) [28–32]. When phosphorylated, 4E-BP1
releases eIF4E to form the eIF4F complex and promote translation
[30,32]. In addition to phosphorylation, sumoylaiton also plays an
important role in this process. Xu et al. demonstrated that eIF4E
modified by SUMO-1 can promote mRNA translation [11].
Moreover, the E3 ligase HDAC2 was shown to promote eIF4E
sumoylation [33]. Here, our study showed that overexpression of
SUMO-2 resulted in a marked increase in translation and a
selective enhancement of key regulators of cell cycle progression,
including c-myc and cyclin D1.
As a reversible post-translational modification, the SUMO
family has gained prominence as a major regulatory component
that impacts numerous aspects of cell growth and differentiation.
Many experiments indicate that SUMO modification is important
for passage through the cell cycle [34–37]. Sumoylation is also
implicated in other forms of cellular growth control, such as
senescence and apoptosis [38–40]. Moreover, the results of the
studies described earlier indicate that sumoylation is not only an
important regulator of the normal function of many vital cellular
proteins but also a contributor in the pathogenesis of some human
diseases. For instance, several lines of evidence point to a role of
the SUMO modification pathway in tumorigenesis [41,42]. Ubc9
overexpression can increase cancer cell growth [43,44]. The
SUMO E3 protein PIAS3 is upregulated in several different
cancer types [45], and elevated levels of the SUMO E1 enzyme
are associated with more severe hepatocellular carcinomas [46].
Additionally, deletion of the protease genes, like Ulp1in yeast,
stops cell cycle progression and further highlights the essential and
critical role of sumolation in the cell’s life cycle [47]. Overexpres-
sion of SUMO-2 and the Uba2 E1 subunit has been correlated
with poor survival of hepatocellular carcinoma patients [46]. In
our study, the cell cycle and apoptosis assays indicate that
overexpression of SUMO-2 promotes cell cycling and inhibits
apoptosis. On the other hand, SUMO-2 depletion inhibits the cell
cycle and promotes apoptosis, which is consistent with previous
studies. We suspect that the observations from our experiments
may be derived from the following two aspects. On one hand,
many cell cycle- and apoptosis-related proteins and kinases are
thought to be the targets of SUMO-2 [48], so it is clear that
SUMO-2 modification plays an important regulatory role in these
cell processes. On the other hand, many cell cycle- and apoptosis-
related proteins are also cap-dependent proteins, which suggests
that faster or slower cell cycle and apoptosis may result from
higher or lower expression levels of these proteins. We hypothesize
that both of them contribute to this phenomena. Thus, our results
further explain the relationship between sumoylation and human
diseases.
Over the past ten years, SUMOs have been established as
essential regulators of many cellular functions. Aberrant SUMO
regulation is a likely cause of a variety of human diseases. While
new SUMO targets are rapidly identified, many fundamental
questions remain unanswered. Our studies show that, like other
components in sumoylation circulation, SUMO-2 can also
promote mRNA translation by regulating the formation of the
eIF4F complex. We believe that our findings could be relevant to
how SUMO-2 participates in physiological and pathological
processes in cells.
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